Genmab | GEN - Assets


Genmab reported DKK12.52B in Assets for its fiscal quarter ending in June of 2026.





Assets Change Date
Agios Pharmaceuticals USD 1.06B 44.38M Sep/2026
Almirall EUR 2.37B 29.97M Jun/2026
Amarin USD 634.08M 9.72M Sep/2026
Amgen USD 96.05B 409M Sep/2026
argenx SE USD 10.03B 1.35B Jun/2026
AstraZeneca USD 119.92B 4.09B Sep/2026
Bayer EUR 113.47B 6.18B Sep/2026
BioMarin Pharmaceutical USD 11.57B 154.21M Sep/2026
Demant DKK 40.03B 951M Jun/2026
Exelixis USD 2.51B 19.26M Sep/2026
Fresenius Medical Care EUR 31.45B 155.97M Sep/2026
Genmab DKK 12.52B 139M Jun/2026
GlaxoSmithKline GBP 71.7B 9.96B Sep/2026
GN Store Nord DKK 30.31B 762M Sep/2026
GRIFOLS EUR 20.28B 191M Sep/2026
Hikma Pharmaceutical USD 5.67B 117M Dec/2025
Insmed USD 2.23B 123.49M Sep/2026
Lakefront Biotherapeutics EUR 3.35B 21.24M Jun/2026
Lonza CHF 18.97B 164M Dec/2025
Merck EUR 53.66B 975M Sep/2026
Novartis USD 117.15B 4.88B Sep/2026
Regeneron Pharmaceuticals USD 44.41B 2.67B Sep/2026
Roche Holding CHF 98.2B 2.5B Jun/2026
Sanofi EUR 130.29B 1.23B Sep/2026
UCB EUR 18.16B 971M Dec/2025